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Abstract: There is an urgent need for new imaging modalities in prostate carcinoma staging.
A non-invasive modality that can assess lymph node and bone metastases simultaneously is preferred.
Epithelial cell adhesion molecule (EpCAM) is a membranous protein of interest as an imaging
target since it is overexpressed in prostatic carcinoma compared with benign prostate epithelium
and compared with stroma. However, EpCAM expression in lymph node metastases is sparsely
available in the literature and EpCAM expression in bone metastases is yet unknown. The current
study evaluates the expression of EpCAM in prostate carcinoma lymph nodes, in matched normal
lymph nodes, in prostate carcinoma bone metastases, and in normal bone by immunohistochemistry.
EpCAM was expressed in 100% of lymph node metastases (21 out of 21), in 0% of normal lymph nodes
(0 out of 21), in 95% of bone metastases (19 out of 20), and in 0% of normal bone (0 out of 14). Based
on these results, EpCAM may be a feasible imaging target in prostate carcinoma lymph node and
bone metastases. Prospective clinical trials are needed to confirm current results. Preoperative
visualization of prostate carcinoma metastases will improve disease staging and will prevent
unnecessary invasive surgery.
Keywords: molecular imaging; imaging target; prostate carcinoma; metastases; epithelial cell
adhesion molecule (EpCAM); immunohistochemistry
1. Introduction
Epithelial cell adhesion molecule (EpCAM), also known as CD326 and 17-1A antigen, is a
transmembrane glycoprotein originally identified as a marker for carcinoma [1]. EpCAM functions as
a cell adhesion molecule in benign and malignant epithelial cells [2]. However, its role also includes
signaling, cell migration, proliferation, and differentiation [1,3,4].
EpCAM has been found expressed in various types of carcinoma, including colon and
rectum, gallbladder, liver, esophagus, lung, head and neck, pancreas, ovarian, breast, and prostate
carcinoma [3–5].
There are several studies that show a significantly elevated expression of EpCAM in prostatic
carcinoma compared with benign prostate epithelium [5–7]. Next, Poczatek et al. and Benko et al.
found that there was no expression of EpCAM in prostate stroma [5,7]. Based on these results, EpCAM
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would be an attractive specific target for imaging purposes in prostate carcinoma. Several preclinical
trials targeted EpCAM for fluorescent and nuclear imaging [8–11]. Results of preclinical fluorescent
imaging are promising for the accurate assessment of tumor margins intraoperatively [11,12]. Thus,
nuclear imaging of EpCAM would be of special interest for prostate carcinoma staging and for
monitoring of treatment response. The importance of correct staging lies in the fact that staging has
huge treatment implications. Metastasized prostate carcinoma cannot be treated curatively. However,
current imaging modalities in prostate carcinoma staging have limitations.
Prostate carcinoma lymph node staging is limited by poor sensitivity and specificity of anatomical
imaging modalities [13–15]. Molecular imaging of lymph node metastases by positron emission
tomography (PET) is booming nowadays. 11C- or 18F-choline PET/CT has good specificity for the
detection of lymph node metastases. However, the sensitivity ranges from 10% to 73% [16,17].
This might result from the target choline, which is not prostate carcinoma-specific. Pelvic lymph
node dissection remains the gold standard for nodal staging. Lymph node dissection has been
associated with regional disease control and better outcome, but this can lead to poor patient outcome
(complications such as lymph edema and thrombosis) and the overtreatment of patients with a low risk
of metastases [18–20]. Therefore, a noninvasive imaging modality to assess lymph node metastases
would be preferred.
For the assessment of bone metastases, skeletal scintigraphy is the most sensitive method.
However, false positive skeletal scintigraphy occurs, for example, from degenerative disease,
inflammation, and trauma. Furthermore, skeletal scintigraphy is hampered by the osteoblastic
response that accompanies bone healing, which can also lead to a false positive diagnosis of disease
progression [21–23]. Furthermore, skeletal scintigraphy lacks anatomical detail, and treatment response
can take about 6 to 8 months before response can be visualized [24,25].
To summarize, there is an urgent need for new imaging modalities in prostate carcinoma staging.
A non-invasive modality, that can assess lymph node and bone metastases simultaneously, is preferred.
This imaging modality should be based on a prostate carcinoma-specific target such as EpCAM.
However, EpCAM expression in prostate carcinoma metastases has been evaluated in only
one study. EpCAM was significantly overexpressed in metastasized prostate carcinoma compared
with benign prostate hyperplasia, which served as a normal control [6]. Since specimens were
collected at autopsies, results should be interpreted with caution. A decay of antigens can be seen in
postmortem specimens.
The current research evaluates the expression of EpCAM in prostate carcinoma lymph nodes,
in matched normal lymph nodes, in prostate carcinoma bone metastases, and in normal bone in order
to determine the feasibility of EpCAM as a specific marker for prostate carcinoma staging.
EpCAM was expressed in 100% of lymph node metastases (21 out of 21), in 0% of normal lymph
nodes (0 out of 21), in 95% of bone metastases (19 out of 20), and in 0% of normal bone (0 out of 14).
Based on these results, EpCAM may be a feasible imaging target in prostate carcinoma lymph node
and bone metastases. Preoperative visualization of these metastases will improve disease staging and
will prevent unnecessary invasive surgery.
2. Results
After immunohistochemistry, one prostate carcinoma lymph node metastasis and four prostate
carcinoma bone metastases were not evaluable due to bad morphology. The matched normal lymph
node was also excluded from statistical analysis. In the end, 20 bone metastases (of 20 patients),
14 normal bone (of 14 patients) and 21 lymph node metastases, and 21 normal lymph node metastases
(of 16 patients) were available for statistical analysis. Clinicopathological parameters of these patients
are presented in Tables 1–3.
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Table 1. Normal lymph nodes and lymph node metastases.
Patient Tissue Type Hormonal Therapy Radiotherapy PS IS TIS
1
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 2 8
2
Lymph node normal No No 0 0 0
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 2 8
Lymph node metastasis No No 4 2 8
3
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 3 12
4
Lymph node normal No No 0 0 0
Lymph node metastasis No No 3 1 3
5
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 3 12
6
Lymph node normal No No 0 0 0
Lymph node metastasis No No 3 3 9
7
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 2 8
8
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 3 12
9
Lymph node normal No No 0 0 0
Lymph node normal No No 0 0 0
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 2 8
Lymph node metastasis No No 4 2 8
Lymph node metastasis No No 4 3 12
10
Lymph node normal No No 0 0 0
Lymph node normal No No 0 0 0
Lymph node metastasis No No 3 2 6
Lymph node metastasis No No 3 1 3
11
Lymph node normal No No 0 0 0
Lymph node metastasis No No 3 1 3
12
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 3 12
13
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 2 8
14
Lymph node normal No No 0 0 0
Lymph node metastasis No No 3 3 9
15
Lymph node normal Yes Yes 0 0 0
Lymph node normal Yes Yes 0 0 0
Lymph node metastasis Yes Yes 4 3 12
Lymph node metastasis Yes Yes 3 3 9
16
Lymph node normal No No 0 0 0
Lymph node metastasis No No 4 2 8
PS: proportion score; IS: intensity score; TIS: total immunostaining score.
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Table 2. Bone metastases.
Patient Tissue Type Hormonal Therapy Radiotherapy PS IS TIS
1 Bone metastasis Unknown Unknown 4 3 12
2 Bone metastasis Unknown Unknown 4 3 12
3 Bone metastasis Yes No 4 3 12
4 Bone metastasis Unknown Unknown 4 3 12
5 Bone metastasis Yes No 4 3 12
6 Bone metastasis No No 4 2 8
7 Bone metastasis Unknown Unknown 0 0 0
8 Bone metastasis Yes Yes 4 2 8
9 Bone metastasis Unknown Unknown 4 3 12
10 Bone metastasis Yes No 3 2 6
11 Bone metastasis Unknown Yes 4 3 12
12 Bone metastasis Yes Yes 4 3 12
13 Bone metastasis Yes Yes 4 3 12
14 Bone metastasis No No 4 3 12
15 Bone metastasis Yes No 3 3 9
16 Bone metastasis Unknown Yes 4 3 12
17 Bone metastasis Unknown Unknown 1 1 1
18 Bone metastasis No No 4 3 12
19 Bone metastasis No No 4 3 12
20 Bone metastasis No No 4 3 12
PS: proportion score; IS: intensity score; TIS: total immunostaining score.
Table 3. Normal bone.
Patient Tissue Type Hormonal Therapy Radiotherapy PS IS TIS
1 Normal bone Unknown Unknown 0 0 0
2 Normal bone Unknown Unknown 0 0 0
3 Normal bone Unknown Unknown 0 0 0
4 Normal bone Unknown Unknown 0 0 0
5 Normal bone Unknown Unknown 0 0 0
6 Normal bone Unknown Unknown 0 0 0
7 Normal bone Unknown Unknown 0 0 0
8 Normal bone Unknown Unknown 0 0 0
9 Normal bone Unknown Unknown 0 0 0
10 Normal bone Unknown Unknown 0 0 0
11 Normal bone Unknown Unknown 0 0 0
12 Normal bone Unknown Unknown 0 0 0
13 Normal bone Unknown Unknown 0 0 0
14 Normal bone Unknown Unknown 0 0 0
PS: proportion score; IS: intensity score; TIS: total immunostaining score. Epithelial cell adhesion molecule
(EpCAM) expression was observed in 21 out of 21 lymph node metastases (100%) and was absent in 21 out of
21 matched normal lymph nodes (100%). Median EpCAM expression (TIS) in lymph node metastases was 8.
Even after hormonal therapy and radiotherapy EpCAM expression was high in 2 lymph node metastases of a
single patient (patient 15). Heterogeneous EpCAM expression was seen in 3 lymph node metastases of patient 9,
in 2 lymph node metastases of patient 10, and in 2 lymph node metastases of patient 15.
EpCAM expression was observed in 19 out of 20 bone metastases (95%) and was absent in 14 out
of 14 cases of normal bone (100%). Median EpCAM expression in bone metastases (TIS) was 12.
After either hormonal therapy or radiotherapy, TIS was high. Even after both hormonal therapy and
radiotherapy, EpCAM expression was high (Table 2).
EpCAM expression was membranous in prostate carcinoma cells of lymph node (Figure 1) and
bone metastases (Figure 2).
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Figure 1. EpCAM expression in lymph node (LN) metastases. Matched normal lymph nodes without 
EpCAM expression (left panel) and lymph node metastases of prostate carcinoma with EpCAM 
expression of intensity score 1: weak; 2: moderate; and 3: strong (right panel). Original magnification: 
200×. 
 
Figure 2. EpCAM expression in prostate carcinoma bone metastases. Bone metastases with EpCAM 
expression of intensity score 1: weak; 2: moderate; and 3: strong. Arrow points towards an area of 
bone metastasis in bone without EpCAM expression. Original magnification: 200×. 
Figure 1. EpCAM expression in lymph node (LN) metastases. Matched normal lymph nodes
without EpCAM expression (left panel) and lymph node metastases of prostate carcinoma with
EpCAM expression of intensity score 1: weak; 2: moderate; and 3: strong (right panel). Original
magnification: 200×.
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Figure 2. EpCAM expression in prostate carcinoma bone metastases. Bone me as ases with EpCAM
expression of inte sity score 1: weak; 2: moderate; and 3: strong. Arrow po nts towards an area of bone
metastasis in bone without EpCAM expression. Original magnification: 200×.
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3. Discussion
In the current study, EpCAM was expressed in 100% of prostate carcinoma lymph node metastases
and 95% of prostate carcinoma bone metastases. The median EpCAM expression was high, with a TIS
of 8 and 12 for lymph node and bone metastases, respectively. EpCAM was not expressed in matched
normal lymph nodes and in non-matched normal bone.
EpCAM expression in prostate carcinoma metastases has been evaluated in only one study
previously. However, bone metastases were not included. EpCAM was significantly overexpressed in
metastasized prostate carcinoma compared with benign prostate hyperplasia, which served as a normal
control [6]. Since specimens were collected at autopsies, results should be interpreted with caution.
The current study is the first to compare EpCAM expression between matched normal lymph
nodes and lymph node metastases and to evaluate EpCAM expression in bone metastases and normal
bone. Absent EpCAM expression in normal lymph nodes and normal bone supports the use of EpCAM
as a target with high specificity for prostate carcinoma.
Went et al. and Benko et al. investigated a possible correlation between EpCAM expression
and nodal stage (N0, N1, or N2) in primary prostate carcinoma. EpCAM expression was defined
as negative, weak to moderate and strong [1]. No correlation was found, presumably caused by
small sample sizes of 10 and 3 primary prostate carcinoma cases, respectively. Moreover, lymph node
specimens were not available in both studies [1,7].
In previous literature EpCAM overexpression was described as TIS > 4 [26]. In the current study,
EpCAM overexpression was found in both lymph node and bone metastases regardless of previous
treatment. This is in agreement with a study from Benko et al. in which a correlation was found
between high EpCAM expression and biochemical recurrence of prostate carcinoma [7]. Next, EpCAM
expression was seen in 82.3% of salvage prostatectomy specimens taken from patients with locally
recurrent prostate carcinoma after external beam radiotherapy or brachytherapy [27].
4. Materials and Methods
Formalin-fixated paraffin-embedded prostate carcinoma lymph node metastases, normal lymph
nodes, prostate carcinoma bone metastases, samples of normal bone, and samples of normal colon were
retrieved from the archives of the Department of Pathology of University Medical Center Groningen.
Lymph node metastases (n = 22) and matched normal lymph nodes (n = 22) were available in 17 patients
who underwent a pelvic lymph node dissection because of a suspicion of nodal involvement on
computed tomography (CT). Of 12 patients, 1 prostate carcinoma lymph node metastasis and 1 normal
lymph node was included; of 3 patients, 2 prostate carcinoma lymph node metastases and 2 normal
lymph nodes were included; of 1 patient, 3 prostate carcinoma lymph node metastases and 3 normal
lymph nodes were included.
Prostate carcinoma bone metastases (n = 24) were available in 24 patients who underwent surgery
to confirm clinical suspicion of prostate carcinoma or to treat skeletal related events. Bone metastases
were taken from several surgical procedures (biopsy (n = 6), osteosynthesis (n = 1), laminectomy (n = 6),
extramedullary excision (n = 1), corporectomy (n = 2), during procedures of hip prosthesis implantation
(n = 1), and other, unknown procedures (n = 7)). Matched normal bone was not available. Fourteen
cases of non-matched normal bone were available in 14 patients who underwent hip prosthesis
implantation. All tissue specimens were anonymously coded. According to Dutch law, no further
Institutional Review Board approval was required (http://www.federa.org/).
Immunohistochemistry was performed in order to determine EpCAM expression. Normal
colon was used as a positive control and omission of the primary antibody on positive control
specimens served as a negative control. After deparaffinization with decreasing grades of alcohol,
antigen retrieval was performed by incubation with 0.1% protease for 30 min at room temperature.
Endogeneous peroxidase was blocked with 0.3% hydrogen peroxide in phosphate buffered saline
(PBS) for 20 min. Slides were incubated with primary mouse monoclonal antibody anti-EpCAM
(clone VU-1D9, Leica Biosystems, Newcastle, UK) diluted at 1:100 in 1% bovine serum albumin and
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phosphate buffered saline (BSA/PBS) for 1 h at room temperature. In the secondary step, slides were
incubated with a rabbit anti-mouse antibody conjugated to polymer-horseradish peroxidase (DAKO,
Glostrup, Denmark), diluted at 1:100 in 1% BSA/PBS with 1% AB serum. In the tertiary step, a goat
anti-rabbit antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was
used, diluted at 1:100 in 1% BSA/PBS with 1% AB serum. Both secondary and tertiary steps required
incubation for 30 min at room temperature. Next, slides were immersed for 10 min in a solution of
0.05% 3,3’-diaminobenzidine (Sigma-Aldrich, Steinheim, Germany) and 0.03% hydrogen peroxide
in PBS for visualization of the signal as brown staining. After washing with demineralized water,
slides were slightly counterstained with hematoxylin, dehydrated, and mounted with Tissue Tec film
(Sakura Finetek, Leiden, The Netherlands).
A pathologist (GJLHvL), blinded to clinical data, scored EpCAM immunoreactivity according to a
previous established method [28]. This method determines a total immunostaining score (TIS), which
is the product of a proportion score (PS) and an intensity score (IS). The PS represents the estimated
amount of positively stained cells (0: none; 1: <10%; 2: 10%–50%; 3: 51%–80%; 4: >80%). IS describes
the estimated staining intensity (0: no staining; 1: weak; 2: moderate; 3: strong). TIS (TIS = PS × IS)
ranges from 0 to 12 with only 9 possible values (0, 1, 2, 3, 4, 6, 8, 9, or 12) [28].
Sensitivity and specificity of EpCAM expression were determined. Specificity of EpCAM
expression could be determined for lymph node specimens only. For bone specimens, specificity could
not be determined due to the lack of negative control bone specimens. Sensitivity is the percentage of
cases with EpCAM expression out of the total amount of either histopathological proven lymph node
metastases or histopathological proven bone metastases. Sensitivity is the percentage of cases without
EpCAM expression in histopathological proven lymph nodes without prostate carcinoma metastasis.
Descriptive statistics were used to describe the results. For ordinal data, the median is presented.
5. Conclusions
In conclusion, the purpose of the current study was to establish the feasibility of EpCAM as
an imaging target for prostate carcinoma lymph node and bone metastases. EpCAM has proved to
be a target with high sensitivity (100%) and specificity (100%) for lymph node metastases and high
sensitivity (95%) and specificity (100%) for bone metastases. Based on previous literature, EpCAM
may be used as imaging target for locally recurrent prostate carcinoma [7,27]. Based on the current
study, EpCAM may be additionally used as an imaging target for prostate carcinoma lymph node
and bone metastases. Preoperative visualization of metastases will improve disease staging and will
prevent unnecessary invasive surgery. Prospective clinical trials are needed to confirm current results.
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